Edition:
United States

Regulus Therapeutics Inc (RGLS.OQ)

RGLS.OQ on NASDAQ Stock Exchange Global Market

0.27USD
4:00pm EDT
Change (% chg)

$-0.00 (-0.22%)
Prev Close
$0.27
Open
$0.27
Day's High
$0.27
Day's Low
$0.26
Volume
73,424
Avg. Vol
115,565
52-wk High
$1.52
52-wk Low
$0.18

Latest Key Developments (Source: Significant Developments)

Regulus Therapeutics Q2 Loss Per Share $0.13
Thursday, 9 Aug 2018 04:05pm EDT 

Regulus Therapeutics Inc ::REGULUS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND RECENT UPDATES.Q2 LOSS PER SHARE $0.13.Q2 EARNINGS PER SHARE VIEW $-0.16 -- THOMSON REUTERS I/B/E/S.CORPORATE RESTRUCTURING AND PIPELINE FOCUS EXPECTED TO EXTEND CASH RUNWAY.  Full Article

Regulus Therapeutics Says Workforce Reduction Of About 60 Pct Is Being Implemented
Thursday, 5 Jul 2018 05:00pm EDT 

July 5 (Reuters) - Regulus Therapeutics Inc ::REGULUS ANNOUNCES STRATEGIC UPDATE AND CORPORATE RESTRUCTURING.REGULUS ANNOUNCES STRATEGIC UPDATE AND CORPORATE RESTRUCTURING.EFFORTS AIMED AT EXTENDING CASH RUNWAY TO MID-2019.WORKFORCE REDUCTION OF APPROXIMATELY 60% IS BEING IMPLEMENTED.RECRUITMENT ACTIVITIES FOR RG-012 CLINICAL PROGRAM IN ALPORT SYNDROME HAVE BEEN PAUSED.ACTIONS ANTICIPATED TO YIELD OVER $20 MILLION OF ANNUALIZED SAVINGS, WHICH ARE INTENDED TO EXTEND CO'S CASH RUNWAY INTO MID-2019.DISCUSSIONS WITH SANOFI TO POTENTIALLY RESTRUCTURE PARTNERSHIP ARE ONGOING.RGLS4326 HAS BEEN GENERALLY SAFE AND WELL-TOLERATED IN PHASE 1 SINGLE ASCENDING DOSE (SAD) AND MAD STUDIES TO DATE.REGULUS THERAPEUTICS - VOLUNTARILY PAUSED PHASE 1 MULTIPLE ASCENDING DOSE STUDY FOR RGLS4326 DUE TO UNEXPECTED OBSERVATIONS IN 27-WEEK MOUSE CHRONIC TOXICITY STUDY.REGULUS- INITIATED INVESTIGATIVE STUDIES, PLANNING NEW 27-WEEK MOUSE CHRONIC TOXICITY STUDY WITH SOME CHANGES BELIEVED TO ADDRESS UNEXPECTED FINDINGS.REGULUS - IN NEAR-TERM, WILL CONCENTRATE EFFORTS ON INVESTIGATING UNEXPECTED MOUSE TOXICITY FINDINGS IN RGLS4326 PROGRAM, ADVANCING HBV PROGRAMS.  Full Article

Regulus Qtrly Net Loss Per Share $0.14
Wednesday, 7 Mar 2018 04:10pm EST 

March 7 (Reuters) - Regulus Therapeutics Inc ::REGULUS REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PIPELINE UPDATE.REGULUS THERAPEUTICS INC - QTRLY NET LOSS PER SHARE $0.14.  Full Article

Regulus Therapeutics Q3 loss per share $0.18
Tuesday, 7 Nov 2017 07:16pm EST 

Nov 7 (Reuters) - Regulus Therapeutics Inc ::Regulus reports third quarter 2017 financial results and recent events.Q3 revenue was less than $100,000.Q3 loss per share $0.18.Q3 revenue view $864,000 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.  Full Article

Regulus Q3 loss per share $0.18
Tuesday, 7 Nov 2017 04:10pm EST 

Nov 7 (Reuters) - Regulus Therapeutics Inc ::Regulus reports third quarter 2017 financial results and recent events.Q3 revenue $100,000.Q3 loss per share $0.18.Q3 revenue view $864,000 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.  Full Article

Regulus Therapeutics Q2 loss per share $0.41
Tuesday, 1 Aug 2017 04:10pm EDT 

Aug 1 (Reuters) - Regulus Therapeutics Inc :Regulus reports second quarter 2017 financial results and recent events.Q2 revenue $100,000.Q2 revenue view $873,000 -- Thomson Reuters I/B/E/S.Q2 loss per share $0.41.Q2 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S.  Full Article

Broadfin Capital reports 5.65 pct passive stake in Regulus Therapeutics - ‍​SEC filing
Monday, 24 Jul 2017 11:24am EDT 

July 24 (Reuters) - Broadfin Capital LLC::Broadfin Capital LLC reports 5.65 percent passive stake in Regulus Therapeutics Inc as of July 20, 2017 - ‍​SEC filing.  Full Article

Regulus Therapeutics prices offering of 44 mln shares at $0.91 per share
Wednesday, 19 Jul 2017 09:45pm EDT 

July 19 (Reuters) - Regulus Therapeutics Inc ::Regulus announces pricing of public offering of common stock.Says public offering of 44.0 million common shares priced at $0.91 per share.  Full Article

Regulus says plans to discontinue clinical development of RG-101
Monday, 12 Jun 2017 07:00am EDT 

June 12 (Reuters) - Regulus Therapeutics Inc :Regulus announces pipeline updates and advancements.Regulus -plans to discontinue clinical development of rg-101 upon completion of one remaining clinical study, which is expected to occur in july 2017.Regulus therapeutics inc says initiation of phase ii clinical programs for rg-012 for treatment of alport syndrome is on track as planned.Regulus therapeutics inc says data from renal biopsy study is anticipated by year-end and interim data from hera is anticipated mid-2018.Regulus -evaluation of clinical data led to identification of a bilirubin transport mechanism as likely cause for cases of hyperbilirubinemia in rg-101 program.Regulus therapeutics inc says ind for rgls4326 is on track for filing by year end 2017.Regulus - astrazeneca informed co that it intends to terminate clinical development program for azd4076 for treatment of nash in type 2 diabetes/pre-diabetes.Regulus -under agreement, astrazeneca's rights with respect to azd4076(rg-125) will revert to regulus when termination becomes effective in twelve months.  Full Article

EcoR1 Capital reports 9.6 pct passive stake in Regulus Therapeutics
Tuesday, 30 May 2017 05:28pm EDT 

May 30 (Reuters) - Regulus Therapeutics Inc :EcoR1 Capital LLLC reports a 9.6 percent passive stake in Regulus Therapeutics Inc as of May 17 - SEC filing.  Full Article

BRIEF-Regulus Reports Q1 Loss Per Share $0.15

* REGULUS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PIPELINE PROGRESS